Evidence map›Paper›PMID 26130665›Full record

ArticleCancer research and treatment2016

Clinical Significance of Peroxisome Proliferator-Activated Receptor γ and TRAP220 in Patients with Operable Colorectal Cancer.

Kyung A Kwon, Jeanho Yun, Sung Yong Oh, Bong-Gun Seo, Suee Lee, Ji-Hyun Lee, Sung-Hyun Kim, Hong Jo Choi, Mee Sook Roh, Hyo-Jin Kim

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Update on genetics and diabetic retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Kyung A KwonDivision of Hematology-Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
Jeanho YunDepartment of Biochemistry, Dong-A University College of Medicine, Busan, Korea.
Sung Yong OhDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Bong-Gun SeoDivision of Hematology-Oncology, Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
Suee LeeDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Ji-Hyun LeeDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Sung-Hyun KimDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Hong Jo ChoiDepartment of Surgery, Dong-A University College of Medicine, Busan, Korea.
Mee Sook RohDepartment of Pathology, Dong-A University College of Medicine, Busan, Korea.
Hyo-Jin KimDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Dong-A University · KRDongnam Institute of Radiological & Medical Sciences · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that regulates expression of mediators of lipid metabolism and the inflammatory response. Thyroid hormone receptor-associated proteins 220 (TRAP220) is an essential component of the TRAP/Mediator complex. The objective of this study was to clarify whether PPARγ or TRAP220 are significant prognostic markers in resectable colorectal cancer (CRC). MATERIALS AND

methodsA total of 399 patients who underwent curative resection for CRC were enrolled. We investigated the presence of PPARγ and TARP220 in CRC tissues and adjacent normal tissues by immunohistochemistry. Correlation between the expression of these factors and clinicopathologic features and survival was investigated.

resultsMedian age of the patients was 63 years (range, 22 to 87 years), and median follow-up duration 61.1 months (range, 2 to 114 months). PPARγ and TRAP220 expression showed significant correlation with depth of invasion (p=0.013 and p=0.001, respectively). Expression of TRAP220 also showed association with lymph node metastasis and TNM stage (p=0.001). Compared with patients with TRAP220 negative tumors, patients with TRAP220 positive tumors had longer 5-year disease-free survival (DFS) tendency (p=0.051). Patients who were PPARγ positive combined with TRAP220 positive had a better 5-year DFS (64.8% vs. 79.3%, p=0.013). In multivariate analysis expression of both PPARγ and TRAP220 significantly affected DFS (hazard ratio, 0.620; 95% confidence interval, 0.379 to 0.997; p=0.048).

conclusionTRAP220 may be a valuable marker for nodal metastasis and TNM stage. Tumor co-expression of PPARγ and TRAP220 represents a biomarker for good prognosis in CRC patients.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorColorectal NeoplasmsDisease-Free SurvivalHumansImmunohistochemistryLymphatic MetastasisMediator Complex Subunit 1Middle AgedNeoplasm StagingPPAR gammaPrognosisYoung AdultBiomarkers, TumorMediator Complex Subunit 1PPAR gammaColorectal neoplasmsMediator complex subunit 1PPARγ

Identifiers

PMID26130665
PMCPMC4720060
OpenAlexW806843107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.